Clinical Trials Logo

Filter by:
NCT ID: NCT02813694 Completed - Clinical trials for Community Acquired Pneumonia

Study to Compare Lefamulin to Moxifloxacin for the Treatment of Adults With Pneumonia

LEAP2
Start date: August 2016
Phase: Phase 3
Study type: Interventional

This study evaluates the safety and efficacy of lefamulin, a pleuromutilin, for the treatment of adults with moderate community-acquired bacterial pneumonia

NCT ID: NCT02813213 Recruiting - Burns Clinical Trials

Effectiveness Comparison of Skin Micro-grafts vs Meshed Split Thickness Skin Grafts

Start date: June 2016
Phase: Phase 4
Study type: Interventional

This is a double-blind randomized controlled clinical trial, that compares the percentage of epithelialization of skin defects using the conventional meshed split thickness skin grafts vs skin micro grafts. Two techniques will be applied in the same patient. The skin defect will be divided in two parts, and with a randomized method each half of this defect will be assigned to one of the two techniques.

NCT ID: NCT02809053 Completed - Clinical trials for Lymphoma, Follicular

A Randomized, Double-blind, Multi-center, Multi-national Trial to Evaluate the Efficacy, Safety, and Immunogenicity of SAIT101 Versus Rituximab as a First-line Immunotherapy Treatment in Patients With Low Tumor Burden Follicular Lymphoma

RAMO-2
Start date: January 18, 2017
Phase: Phase 3
Study type: Interventional

This is a Randomized, Double-blind, Multi-center, Multi-national Trial to Evaluate the statistical equivalence of efficacy, safety and immunogenicity of SAIT101 Versus Rituximab as a First-line Immunotherapy Treatment in asymptomatic patients with Low Tumor Burden Follicular Lymphoma.

NCT ID: NCT02808975 Completed - Clinical trials for Hidradenitis Suppurativa (HS)

Safety and Efficacy of Adalimumab (Humira) for Hidradenitis Suppurativa (HS) Peri-Surgically

SHARPS
Start date: July 18, 2016
Phase: Phase 4
Study type: Interventional

The objective of this study was to assess the safety and efficacy of adalimumab prior to surgery in participants with moderate to severe Hidradenitis Suppurativa (HS) who were surgical candidates.

NCT ID: NCT02807636 Completed - Clinical trials for Urothelial Carcinoma

Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma

IMvigor130
Start date: June 30, 2016
Phase: Phase 3
Study type: Interventional

A Phase III, randomised study of atezolizumab alone and in combination with chemotherapy versus chemotherapy alone in participants with untreated advanced urothelial cancer.

NCT ID: NCT02805530 Completed - Clinical trials for Carcinoma, Non-Small-Cell Lung

Radical Treatment of Synchronous Oligometastatic Non-Small Cell Lung Carcinoma

Start date: June 2015
Phase: N/A
Study type: Interventional

Non-small cell lung cancer (NSCLC) is the most frequent neoplasm worldwide and also represents the main cause of cancer death. However, it represents the main cause of death by cancer. The prognosis of survival at 5 years is poor, approximately 13-15%. Various studies suggest that patients who clinically present with a limited number of metastases, a term defined as oligometastatic disease, could have a better prognosis of survival with a radical treatment, than for their counterparts with a greater number of metastasis. The purpose of this study is to add more information to the current medical literature about the benefits in overall survival of radical treatment of oligometastatic disease in patients with NSCLC and equal or less than 5 synchronous metastases at the time of diagnosis. The outcomes of the study are to determine the global survival and progression-free survival in patients with synchronous oligometastatic (equal to or less than 5 sites) advanced NSCLC undergoing radical treatment of all metastatic sites and the primary tumor.

NCT ID: NCT02805257 Completed - Glaucoma Clinical Trials

Ahmed Glaucoma Valve Surgery With Mitomycin-C

AMCT
Start date: June 2016
Phase: Phase 2
Study type: Interventional

This study will determine the effectiveness of Mitomycin-C use in the glaucoma surgery Ahmed valve implantation. Approximately 100 patients will be enrolled, with half receiving the Mitomycin-C treatment and the other half receiving placebo treatment.

NCT ID: NCT02804763 Completed - Clinical trials for Systemic Lupus Erythematosus (SLE)

A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus

Start date: June 2, 2016
Phase: Phase 2
Study type: Interventional

The purpose is to evaluate the efficacy and safety of three different doses of Dapirolizumab Pegol (DZP) versus placebo in adult subjects with moderately to severely active systemic Lupus Erythematosus.

NCT ID: NCT02804698 Completed - Diabetes Clinical Trials

Tools And Practices To Decrease CVD And Complications In The Diabetic Population Of Mexico

Start date: August 2016
Phase: N/A
Study type: Interventional

This project will look to improve standards of care for diabetic patients by evaluating a program that supports participants in making healthy lifestyle changes. The program consists of 13 educational sessions that contain information about the prevention and care of diabetes and cardiovascular disease, physical activity, nutrition, community health and emotional well being.

NCT ID: NCT02803918 Completed - Clinical trials for Type 2 Diabetes Mellitus

A Study on Safety, Pharmacokinetics and Pharmacodynamics of Lixisenatide in Pediatric Patients With Type 2 Diabetes Mellitus (T2DM)

Start date: May 17, 2017
Phase: Phase 1
Study type: Interventional

Primary Objective: To demonstrate safety of 14-day repeated lixisenatide doses with 3 ascending doses as compared to placebo in pediatric patients with T2DM. Secondary Objectives: - To evaluate plasma concentrations of lixisenatide after repeated doses (3 ascending doses) and pharmacokinetic parameters of repeated lixisenatide doses in pediatric patients with T2DM. - To evaluate the change from baseline in fasting and post-prandial plasma glucose concentrations during a standardized meal test after 3 ascending repeated doses of lixisenatide in comparison to placebo.